Introduction: T-cell immunoregulatory cytokines influence the persistence of hepatitis C and B virus (HCV, HBV) chronic infection and the extent of liver damage. Th1 cytokines positively correlate with hepatic inflammation in HBV and HCV chronic infection. The proinflammatory cytokines are involved in viral clearance and in metabolic and viral hepatic diseases, respectively. The aim of this study is to evaluate the biochemical, haematological parameters and profile of Th1/Th2 cytokines in HCV and HBV hepatitis before and after treatment with BioR. Methods: The study included 42 patients with chronic viral hepatitis. Following the aim the establishment of the viral hepatitis aetiology it was decided to define the markers of the viral hepatitis, the antibodies antiHCV total, antiHCV IgM, HbsAg, antiHBs, antiHBcor total and IgM, as well as to identify the alcohol consumption through use of different questionnaires. Along with the evaluation of the liver status also the abdominal ecography and the hepatic gamma-scintigraphy or scanning of the liver has been performed. The immunoenzymatic assay has been used to study the interleukins 1, 10 and TNF-alpha. Patients included in the study have been administered the injection solution of BioR, 1.0 ml intramuscular, daily, during 10 days. Results: Our study has indicated that BioR causes a number of haematological actions in case of patients with HCV. Thus, patients with HCV show a real amelioration of haemoglobin (p<0.05), and of lymphocyte levels (p<0.05) compared to patients with HBV. In result of the application of a therapy with BioR an evident diminution of cytolysis (ALT, AST) takes place both in patients with HBV (p<0.05) and in the ones with HCV (p<0.05). This indicates the fact that BioR plays the role of a hepatic protector. It has been also proven that BioR reduces gamma GTP in patients with HCV (p<0.05) compared to patients with HBV (p>0.05), indicating to the occurrence of a disintoxication. This study has shown that a treatment with BioR brings about the stimulation of production of IL 10, TNF alpha in patients with HCV and HBV. We consider this action a key mechanism of this preparate with antiviral effect, and we recommend it for treatment of persons with viral hepatitis. Conclusions: This study indicates that the use of the BioR preparate in chronic viral B and C hepatitis is justified, given the fact that it acts as a hepatic protector, causes haematological regulation and has the disintoxication and immune-modulation effects